Skip to main content
OpenTrials
Completed

NCT Number: NCT03152019

Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT)

The recognized manifestations of HHT are all due to abnormalities in vascular structure. Epistaxis due to telangiectases formation is spontaneous, very variable, recurrent in 90% of patients, and associated with severe anemia in 2-10%. They also significantly reduce quality of life.

Improvement in epistaxis has been shown in HHT patients after a liver transplantation. It was hypothesized that the immunosuppressive treatment (FK506) used to prevent rejection may have an anti-angiogenic effect.

The results of Albiñana et al suggest that the mechanism of action of FK506 involves a partial correction of endoglin and ALK1 haplosufficiency, genes responsible for 90% of HHT case.

Tacrolimus ointment is available on the market for the treatment of eczema and can therefore readily be used as it is for nasal administration. Topical nasal administration of tacrolimus may be an easy local ENT treatment that is non-aggressive and results in little trauma for the patient in relation to other first line treatment possibilities.

The main objective of this trial is to evaluate, at 6 weeks after the end of the treatment, the efficacy on the duration of nosebleeds, of 6 weeks tacrolimus nasal ointment application, in patients with HHT complicated by nosebleeds (30 min/6 weeks). Secondary objectives are to evaluate the tolerance throughout the study, the efficacy on anemia and on clinical parameters (nosebleeds, quality of life, epistaxis severity score questionnaire and blood transfusions) and the systemic absorption of nasal administration.

This is a multicenter prospective and double blinded phase I/II trial. A total of 48 patients will be randomized versus placebo using an allocation ratio of 1:1. The ointment (Protopic® at 0.1% or placebo) will be self-administered by the patient with one administration in each nostril twice a day for 6 consecutive weeks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hemorrhagic Hereditary Telangiectasia (HHT) Cardiovascular Abnormalities Cardiovascular Diseases Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Telangiectasia, Hereditary Hemorrhagic Telangiectasis Vascular Diseases Vascular Malformations

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Hôpital Femme Mère Enfant, Bron, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years.
  • Patients who have given their free, informed and signed consent.
  • Patients affiliated to a social security scheme or similar.
  • Patients monitored for clinically confirmed HHT (presence of at least 3 Curaçao criteria) and/or confirmed by molecular biology.
  • Patient presenting nosebleeds with total duration > 30 minutes for 6 weeks prior to the time of inclusion justified by completed follow-up grids.

Exclusion criteria

  • Women who are pregnant or nursing (lactating), women of child-bearing potential without reliable contraception.
  • Patients not affiliated to a social security scheme.
  • Patients who are protected adults under the terms of the law (French Public Health Code).
  • Refusal to consent.
  • Patients for whom the diagnosis of HHT has not been confirmed clinically and/or by molecular biology.
  • Participation in another clinical trial which may interfere with the proposed trial (judgment of the investigator).
  • Patients who have undergone nasal surgery in the 6 weeks prior to inclusion.
  • Known hypersensitivity to macrolides in general, to tacrolimus or to any of the excipients.
  • Patient with an inherited skin barrier disease such as Netherton's syndrome, lamellar ichtyosis, generalized erythroderma, graft-versus-host skin disease, or suffering from generalized erythroderma.
  • Patient with CYP3A4 inhibitors treatment, e.g. erythromycin, itraconazole, ketoconazole and diltiazem.
  • Patients who have incompletely filled in the nosebleed grids in the 10 weeks preceding the treatment. If there is missing data for more than 7 days, the patient cannot be included.
  • Patients who do not present nosebleeds with a total duration of > 30 minutes for 6 weeks prior to the time of inclusion.
  • Patients with ongoing immunosuppressive treatment.
  • Patients with known and symptomatic immune deficiency

Treatment and study plan

Protopic® (Tacrolimus) 0.1% ointment

Drug

About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.

Placebo

Drug

About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.

Primary outcomes

  1. Percentage of Patients Experiencing an Improvement in Their Nosebleeds

    Time frame: up to 12 weeks

    Efficacy of tacrolimus nasal ointment on nosebleeds when administered for 6 weeks

Secondary outcomes

  1. Adverse Events

    Time frame: up to 12 weeks

    Tolerance will be evaluated by recording adverse reactions and adverse events during the treatment period and the follow up period and by clinical examinations during the follow-up period.

  2. Number of Epistaxis

    Time frame: up to 12 weeks

    Evaluate efficacy on clinical criteria : epistaxis frequency before and after treatment.

  3. Epistaxis Duration

    Time frame: up to 12 weeks

    To evaluate efficacy of tacrolimus nasal ointment on duration of nosebleeds before and after treatment.

  4. Hemoglobin Level

    Time frame: up to 12 weeks

    before and after treatment.

  5. Ferritin Level

    Time frame: up to 12 weeks

    before and after treatment.

  6. Quality of Life Assessed by SF36 Questionnaire

    Time frame: up to 12 weeks

    To evaluate efficacy on quality of life with SF36 before and after treatment

  7. Severity Epistaxis Score Assessed by ESS Questionnaire

    Time frame: up to 12 weeks

    To evaluate efficacy on severity epistaxis score with ESS before and after treatment.

  8. The Percentage of Patient With Tacrolimus Detection in the Blood

    Time frame: up to 6 weeks

    To evaluate systemic absorption after tacrolimus nasal administrations.

  9. the Level of Exposure of Patient With Tacrolimus Detection in the Blood.

    Time frame: up to 6 weeks

    To evaluate systemic absorption after tacrolimus nasal administrations.

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT) - A Double Blind, Randomized, Placebo-controlled, Multicenter Trial

Acronym: TACRO

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
May 12, 2017
Registry last updated
Jul 1, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.